fbpx

December 20, 2019

Should you buy Outlook Therapeutics (OTLK) in 2020?

Outlook Therapeutics (OTLK) is a clinical stage bio-pharmaceutical working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications. Outlook Therapeutics’

Contributing Writers Wanted

Stockpence is currently seeking to expand our team of contributors. We’re looking for financial gurus & article writers to write about trending market news and investment ideas about the stock market.

If you’re interested please contact us!

Categories

Don't Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts and our next featured stock!
  • This field is for validation purposes and should be left unchanged.

Scroll to Top